Activation of group I metabotropic glutamate receptors (mGluRs) leads to a concerted modulation of spike afterpotentials in guinea pig hippocampal neurons including a suppression of both medium and slow after-hyperpolarizations (AHPs). Suppression of AHPs may be long lasting, in that it persists after washout of the agonist. Here, we show that persistent AHP suppression differs from short term, transient suppression in that distinct and additional signaling processes are required in order to render the suppression persistent. Persistent AHP suppression followed DHPG application for 30 min, but not DHPG application for 5 min. Persistent AHP suppression was temperature-dependent, it occurred at 30 -31ºC, but not at 25 -26ºC. Preincubation of slices in inhibitors of protein synthesis (cycloheximide or anisomycin) prevented the persistent suppression of AHPs by DHPG. Similarly, preincubation of slices in an inhibitor of p38 MAP kinase (SB 203580) prevented persistent AHP suppression. In contrast, a blocker of p42/44 MAP kinase activation (PD 98059) had no effect on persistent AHP suppression. Additionally, we show that the mGluR5 antagonist MPEP, but not the mGluR1 antagonist LY 367385, prevented DHPG-induced persistent AHP suppression. Thus, persistent AHP suppression by DHPG in hippocampal neurons requires activation of mGluR5. In addition, activation of p38 MAP kinase signaling and protein synthesis are required to impart persistence to the DHPG-activated AHP-suppression.
INTRODUCTION
Metabotropic glutamate receptors (mGluRs) are widespread regulators of brain activity. Among the phenomena in which mGluRs play an excitatory role are epileptiform burst generation (Arvanov et al. 1995; Chuang et al. 2001 Chuang et al. , 2005 Lee et al. 2002; Sayin and Rutecki 2003; Young et al. 2004; Zhao et al. 2004) , and long-term potentiation (LTP; Anwyl 1999; Bortolotto et al. 1999) . The mechanisms of the mGluR contribution to these phenomena are understood to some extent, and may involve suppression of the post-action potential after-hyperpolarization (AHP). Group I mGluR-induced epileptiform burst generation is facilitated by suppression of the AHP and by induction of a voltage dependent inward current (Chuang et al. 2001; Martin et al. 2001; Young et al. 2004) . LTP can be facilitated, or primed, by the excitability increase that follows from mGluR block of the AHP (Cohen et al. 1999; Sourdet et al. 2003) . Moreover, the importance of AHP suppression by various transmitters to increased excitability and learning in a number of brain areas is widely reported (Moyer et al. 1996; Oh et al. 2003; Saar et al. 1998 Saar et al. , 2001 Thompson et al. 1996) . In particular, prolonged AHP suppression has been associated with hippocampus-dependent learning (Ohno et al. 2006; Zelcer et al. 2006; Zhang and Linden 2003) . Thus, it is of considerable interest that group I mGluR-induced AHP suppression may persist for extended periods after agonist has been washed out (Cohen et al. 1999; Ireland and Abraham 2002) . At present, the signaling pathways that lead to long-term group I mGluR-mediated effects are not well understood. This paper attempts to further that understanding by experimentally distinguishing between transient and persistent AHP suppression by group I mGluRs, and by showing that persistent block of the AHP involves additional steps that need not be activated when the AHP is suppressed in the presence of agonist.
Both medium AHPs (mAHPs), which, in CA3, are mediated predominantly by the voltage-sensitive, intracellular Ca
2+
-insensitive M-current, and slow AHPs (sAHPs), which are mediated by an unidentified Ca 2+ -sensitive channel, are present in CA3 pyramidal cells (Storm 1990; Vogalis et al. 2003) . They contribute to spike frequency adaptation and the suppression of both AHPs has been implicated in epileptogenesis (Cooper et al. 2000; Martin et al. 2001; Fernandez de Sevilla et al. 2006; Pena and Alavez-Perez 2006; Tallent et al. 2001 ). The mAHP is readily apparent in CA3 pyramidal cells following single action potentials, whereas sAHPs become prominent only after repeated spikes. We examined the suppression of both mAHPs and sAHPs by the specific group I mGluR agonist (S)-3,5-dihydroxyphenylglycine (DHPG), and addressed the conditions that led to their persistent suppression.
We found that persistent AHP suppression was induced by extended agonist exposures (30 min, but not 5 min) and that persistence was selectively inhibited at reduced 
METHODS

Slice preparation
Animal use procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the State University of New York Downstate Medical Center.
Transverse hippocampal slices (about 300 µm-thick) were prepared as previously described (Bianchi and Wong 1995) . Briefly, guinea pigs (250 to 350 g) were anaesthetized with halothane by inhalation and decapitated in conformity with the IACUC guidelines (protocol number 0619404). The heads were removed. Hippocampi were dissected and sliced in icecold artificial cerebro-spinal fluid (aCSF; see below) using a vibratome (The Vibratome Company, St. Louis, MO, USA). Slices were stored in aCSF at 30 o C for one half hour and then at room temperature for at least one half hour before use. One slice at a time was Slices were held against the cover slip bottom of the chamber by nylon threads that were stretched across a platinum ring. Slices were thus prevented from moving while allowing solution exchange on the underside of the slice. The recording chamber was held in a steel plate attached to the mechanical stage of a Nikon Diaphot microscope. The various micromanipulators were attached to the same plate.
Electrophysiological recordings
Conventional electrophysiological recording techniques were used and have been described previously (Bianchi et al. 1999) . Glass micropipettes pulled from thin-walled capillaries (TW100F; World Precision Instruments, Sarasota, FL, USA) and filled with 2 M potassium acetate (resistances typically 30 to 50 MK) were used for current clamp recordings of CA3 pyramidal cells. Voltage signals were amplified, and intracellular current injected using an Axoclamp 2B amplifier (Molecular Devices, Sunnyvale, CA USA). Recordings were displayed on an oscilloscope (DSO 400, Gould Instruments, Valley View, OH, USA) and chart recorder (Gould TA240), were stored on FM tape (Store 4DS, Racal, Southampton, UK), and were low-pass filtered (8-pole Bessel, -3dB at 1 kHz), and sampled at 5 kHz for storage and later analysis by computer (pCLAMP6, TL-1; Molecular Devices). Each cell was maintained at a given preset hyperpolarized membrane potential (-67.1 ± 0.7 mV, mean ± standard error of the mean, S.E.M.; n = 31) with current injection in order that the increased activity following introduction of DHPG would not raise spontaneous spike frequency to the point that AHPs were difficult to isolate. For each independent experiment, the membrane potential was preset to a value that varied within 2 mV (membrane potentials are labeled next to the traces shown in all figures). In cases where the membrane potential chosen prior to addition of DHPG did not prevent high spontaneous spike rates during and after DHPG, or where doublet or triplet spiking following DHPG could not be avoided, the data were not used. Hyperpolarizing the cells Page 5 of 40 also reduced the appearance of a voltage-dependent, group I mGluR-induced afterdepolarization (Young et al. 2004) . Single action potentials, used to elicit mAHPs, were triggered by 3-4 ms square current pulses of 0.2 to 2.5 nA. Action potential bursts, used to stimulate sAHPs, were triggered by 100 ms square-wave current injections in the same amplitude range. Slow AHPs were monitored less frequently than mAHPs, but because sAHPs were less affected by spontaneous activity (see Fig. 3A ), they could often be monitored for a longer time (Figs. 3, 4 , and 5). Hyperpolarizing current pulses (-0.2 to -0.5 nA; 150 ms) were applied periodically to monitor cell input resistance and to adjust the bridge balance. Input resistance (in MK) was calculated as: amplitude of the voltage deflection at the end of a 150 ms hyperpolarizing current injection (mV) divided by the amplitude of the current (nA).
Pharmacological agents
Control solution contained 6-cyano-7-nitroquinoxyline-2,3-dione (CNQX; 10 µM) and 3-((R,S)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP; 20 µM) in aCSF to block ionotropic glutamate receptors. Group I mGluRs were activated using the specific agonist (S)-3,5-dihydroxyphenylglycine (DHPG; 10 -50 µM), which was applied by addition to the superfusing solution. DHPG applications were for either 1 -5 min (brief, < 5min), beginning when DHPG entered the recording chamber (evidenced by depolarization (SB 203580, 5 -20 µM; Cuenda et al. 1995; Wang et al. 2007 ). Slices were pre-treated with kinase blockers for at least 1 hour prior to recording. Block of mGuR1 or mGuR5 was accomplished using (S)-(+)-T-amino-4-carboxy-2-methylbenzeneacetic acid (LY 367385, 100 µM) or 2-methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP, 50 µM) respectively, in aCSF. DHPG, CNQX, CPP, cycloheximide, anisomycin, PD 98059, SB 203580, LY367385, and MPEP were purchased from Tocris Bioscience (Ellisville, MO, USA). All other chemicals were from Sigma-Aldrich (St. Louis, MO, USA).
Measurements and statistical analysis
All measurements were made in the presence of CNQX and CPP. 
RESULTS
A total of 75 CA3 pyramidal cells with resting potentials less than or equal to -60 mV and overshooting action potentials was used for this study. One cell was recorded from each slice used. Cells were held at constant membrane potential by manually adjusting the injected current to suppress spontaneous action potentials, in the range of -60 to -70 mV (see Methods). Input resistance was monitored periodically and recording was stopped if it fell below 80% of its baseline, pre-DHPG value (baseline R in = 45.9 ± 3.4 MK; n = 28).
Stimulus duration dependence
We first exposed guinea pig hippocampal slices to varying concentrations of DHPG from 10 µM to 50 µM and to exposure times from 1 to 30 min. DHPG at any concentration between 10 and 50 µM caused suppression of the AHP (both medium and slow), and there was no marked relationship between DHPG concentration and persistence of AHP Page 8 of 40 suppression after drug washout. In contrast, varying the duration of DHPG treatment had a dramatic effect on duration of the AHP block. After a brief (< 5 min) exposure to DHPG, suppressed AHPs often recovered within 20 to 30 min after agonist washout. When DHPG treatments were extended to 30 min, AHP suppression persisted after agonist washout for the duration of the recording (up to 100 min; see for example Fig. 1B) . Figure 1A illustrates the block and subsequent recovery of mAHPs following single action potentials in a cell exposed to brief DHPG treatment, as contrasted to the AHP block and absence of recovery in a cell treated with DHPG for 30 min. Figure 1B shows the time course of mAHP amplitude (as % of control) during control, DHPG exposure, and DHPG washout, for the same two cells. Figure 1C summarizes the data from 21 cells, 11 cells treated with DHPG for < 5 min, and 10 cells treated for 30 min. AHPs were triggered by single action potentials produced by 3 -4 ms depolarizing pulses. Medium AHP amplitude was measured at 150 ms after the spike (Methods) and was expressed as percent of control mAHP amplitude for each cell.
The mAHP was suppressed by DHPG and the degree of mAHP suppression was not significantly different between short and long DHPG exposures. AHPs were suppressed to -27 ± 18.5% of control (n = 11) for the 5 min treatment and to -8.5 ± 16.9% of control (n = 10) for the 30 min treatment. Baseline membrane potentials were -65.6 ± 0.8 mV (n = 11) for 5 min DHPG and -66.8 ± 0.8 mV (n = 10) for 30 min DHPG treatments. Control values of mAHP amplitude also did not differ significantly in the two cases (-2.5 ± 0.3 mV (n = 11) for 5 min DHPG treatment, and -2.5 ± 0.4 mV (n = 10) for 30 min DHPG treatment). However, the recovery of the mAHP after brief DHPG treatment was significantly faster than that after 30 min DHPG treatment (interaction of drug washout time and DHPG treatment duration, P < 0.001, Methods). By 25 min after DHPG washout, and from that point on, mAHP amplitude was significantly larger (P V 0.007) after a brief DHPG treatment than it was after 30 min of DHPG. Medium AHP amplitudes during DHPG washout were also fitted with linear regressions (Methods). The recovery rate after 5 min, but not that after 30 min of DHPG, was significantly greater than zero (P < 0.001 as opposed to P = 0.07). Thus, after a 5 min DHPG treatment, the suppressed mAHP had fully recovered by about 30 min of washout. After a 30 min treatment with DHPG, the mAHP was similarly suppressed and did not significantly recover.
Temperature dependence
The results illustrated in Figure 1 produced by the two treatments did not differ significantly. Measurements at 15 min of washout were used to approximate the degree of suppression by DHPG. There was no significant difference in suppression between 5 min (19.0 ± 9.2% of control; n = 6) and 30 min (35.1 ± 15.4%; n = 9) treatment groups. Control sAHP amplitude was -8.9 ± 0.5 mV (n = 6) for the 5 min DHPG treatment, and -9.0 ± 0.9 mV (n = 9) for 30 min treatments.
Baseline membrane potentials were -66.9 ± 0.3 mV (n = 6) in cells treated for 5 min, and -66.9 ± 1.2 mV (n = 9) in cells treated for 30 min.
Thus, the mechanism(s) for persistent suppression appeared similar for the medium and slow AHPs, in that they shared a similar dependence on the duration of agonist exposure and a similar sensitivity to temperature.
Effects of protein synthesis inhibitors
Following pretreatment with, and in the presence of, cycloheximide or anisomycin, mAHPs were evoked by single action potentials and sAHPs by bursts of action potentials (Fig. 5) . Mean AHP values recorded in the presence of cycloheximide (mAHP: -2.7 ± 0.7 mV, n = 5; sAHP: -9.4 ± 1.2 mV, n = 5; Fig. 5A Figure 5F shows that in cycloheximide DHPG suppressed sAHPs by 70.4 ± 7.6% (n = 5, cycloheximide, black bar) as opposed to 89.2 ± 16.5% in control solution (n = 6, aCSF, black bar). Likewise, in anisomycin, neither the mAHP nor the sAHP amplitudes before DHPG application differed from those recorded in control solution (mAHP: -3.2 ± 0.7 mV, n = 5; sAHP: -9.7 ± 0.7 mV, n = 5). The degree of AHP suppression by DHPG was also unaffected by the presence of anisomycin (mAHP: 108.2 ± 17.0%; n = 5; Fig. 5E , anisomycin, black bar; sAHP: 85.6 ± 5.5%; n = 5; Fig. 5F , anisomycin, black bar). However, persistence of AHP suppression by DHPG was blocked in cells exposed to cycloheximide or anisomycin (Figs. 5E and F) . The AHP suppression remaining at 30 -60 min following DHPG washout in the presence of protein synthesis inhibitors at 30 -31°C (Fig. 5E : mAHP in cycloheximide, gray bar: 16.7 ± 10.5%; n = 5; and mAHP in anisomycin, gray bar: 12.8 ± 9.5%; n = 5; Fig. 5F : sAHP in cycloheximide, gray bar: 7.1 ± 9.5%; n = 5; and sAHP in anisomycin, gray bar: 19.7 ± 8.6%; n = 5) was significantly smaller (P < 0.01) than that measured in the absence of inhibitors (Fig. 5E : mAHP in aCSF, gray bar: 86.5 ± 6.5%; n = 5; and sAHP in aCSF, gray bar: 89.2 ± 16.5%; n = 6). The remaining AHP suppression in protein synthesis inhibitors was not significantly different from that obtained in cells recorded at the reduced temperature of 25 -26°C in control solution (mAHP suppression: 24.6 ± 6.9%; n = 5; and sAHP: 8.0 ± 6.5%; n = 6).
Effects of MAP kinase inhibitors
Having determined that the additional pathway elements leading from transient to persistent AHP suppression included synthesis of new protein, we next attempted to identify pathway intermediates that led to the required protein synthesis. Two sets of experiments were done in which MAP kinases were inhibited with either PD 98059 on the one hand, or SB 203580 on the other, which inhibit activities of p42/44 or p38 MAP kinases, respectively (Cuenda et al. 1995; Dudley et al. 1995; Wang et al. 2007 ). Pretreatment of slices for one hour with PD 98059 had no significant effect on the persistence Fig. 6A and B, Control: mAHP, -2.1 ± 0.4 mV, n = 5; sAHP, -7.1 ± 1.7 mV, n = 4; and for slices incubated in SB 203580, Fig. 6A and B, Control: mAHP, -3.8 ± 0.5 mV, n = 5; sAHP, -8.5 ± 0.7 mV, n = 6). Nor was the suppression of AHPs during DHPG treatment affected by either of the MAP kinase blockers (for slices incubated in PD 98059, Fig. 6E and F, black bars: mAHP, 103.1 ± 9.4%, n = 5; sAHP, 91.8 ± 11.0%; n = 4; and for slices incubated in SB 203580, Fig. 6E and F, black bars: mAHP, 96.3 ± 13.8%, n = 5; sAHP, 84.3 ± 7.7%, n = 6). In addition, PD 98059 had no effect on AHP recovery during washout of DHPG. For slices incubated in PD 98059 ( Fig. 6E and F, gray bars) , AHP suppression 30 -60 min after washout of DHPG were: mAHP, 82.9 ± 6.4% (n = 5); sAHP, 68.6 ± 10.2% (n = 4). Inhibition of p38 MAP kinase, however, blocked persistence of AHP suppression (Fig. 6E and F, SB 203580, gray bars) . Suppression of both mAHPs and sAHPs was significantly reduced after DHPG washout in the presence of SB 203580: mAHP, 28.5 ± 2.5% (P < 0.01; n = 5); sAHP, 16.7 ± 6.5% (P < 0.01; n = 5).
Involvement of mGluR1 and mGluR5 in Persistent AHP Suppression
The two group I mGluRs, mGluR1 and mGluR5, may activate different physiological responses (e.g. Mannaioni et al. 2001; Chuang et al. 2002) . For example, mGluR5 is thought to be selectively responsible for mGluR-LTD in CA1 (Fitzjohn et al. 1999; Anwyl 2006) . Thus, a final set of experiments was performed to test whether mGluR1 and mGluR5 contribute equally to AHP suppression and its persistence following 30 min DHPG treatment. Either mGluR1 or mGluR5 was blocked using LY 367385 or MPEP respectively (Methods). Figure 7 shows that blocking mGluR5, but not mGluR1, significantly reduced persistence of AHP suppression.
Neither MPEP nor LY 367385 affected AHP amplitude in control solution or suppression by DHPG. AHP amplitudes in control solution ( Fig. 7A and B, Control) were: mAHP, -3.1 ± 0.8 mV, n = 5; sAHP, -7.9 ± 0.6 mV, n = 5, for slices in MPEP; mAHP, -2.9 ± 0.1 mV, n = 5; sAHP, -6.3 ± 1.6 mV, n = 5, for slices in LY 367385. During DHPG treatment, AHP suppression was not affected by either blocker (for slices in MPEP, Fig. 7E and F, black bars: mAHP, 112.2 ± 13.7%, n = 5; sAHP, 93.6 ± 7.2%, n = 5; and for slices in LY 367385, Fig. 7E and F, black bars: mAHP, 105.6 ± 13.0%, n = 5; sAHP, 88.6 ± 8.7%, n = 5). At 30 -60 min of DHPG washout, AHP suppression was clearly reduced in slices treated with MPEP compared to slices either without blockers or treated with LY 367385 (for slices in MPEP, Fig. 7E and F, gray bars: mAHP, 13.2 ± 9.3%, n = 5, P < 0.01; sAHP, 16.2 ± 4.1%, n = 5, P < 0.01; and for slices in LY 367385, Fig. 7E and F, gray bars: mAHP, 86.2 ± 15.1%, n = 5; sAHP, 69.8 ± 9.7%, n = 5). 1996a,b; Desai and Conn 1991; Gereau et al. 1995; Heuss et al. 1999; Nouranifar et al. 1998) , while others at 30°C or 32°C (Cohen et al. 1999; Hu and Storm 1991; Ireland and Abraham 2002) . Our data indicate that persistent AHP suppression could not be induced at the low temperature of 25 -26°C. Indeed, data obtained by the groups listed above using temperatures lower than 28°C reported transient AHP suppression following group I mGluR stimulation. Our results also suggest that experimental temperature is an important parameter in the study of group I mGluR-mediated plasticity processes.
The temperature-sensitivity of persistent AHP suppression may be due to the suppression of some biochemical processes necessary for its induction. The requirement of protein synthesis for persistent AHP suppression (Fig. 5) Finally, our data reveal that persistent AHP suppression was induced by mGluR5 but not mGluR1. In this regard, it is interesting to know that mGluR5, but not mGluR1, has 
